Sotatercept Endorsed for PAH by ICER

Drug's novel mechanism of action raises hopes of disease-modifying activity, but long-term cost-effectiveness rests on improvement in functional status.

Related Keywords

California ,United States ,San Francisco ,American ,Greg Curfman ,Marc Simon ,Effectiveness Public Advisory Council ,World Health Organization ,Drug Administration ,Midwest Institute For Clinical ,University Of California ,European Respiratory Society ,Pulmonary Hypertension Center ,Harvard Medical School ,Journal Of The American Medical Association ,European Society Of Cardiology ,Midwest Institute ,Economic Review ,Comparative Effectiveness Public Advisory Council ,American Medical ,Pulmonary Arterial Hypertension ,Ah Pulmonary Arterial Hypertension ,Utah ,Prostacyclins ,Endothelin Receptor Antagonists ,Europe ,European ,Intravenous ,V Intravenous ,Intravenous Route ,Receptors ,Connective Tissue Disease ,Heart Failure ,Hypertension ,Adverse Effects ,Side Effects ,Blood ,Clinical Guidelines ,Guidelines ,Comparative Effectiveness ,Us Food And Drug Administration ,